Covered recipient · General Payments record
VIJAYKUMAR M RAO
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$3,233.69
- Reported across 66 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $724.38 | 11 |
| Education | $24.61 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Retrophin, Inc. | $213.09 | 1 |
| Amgen Inc. | $163.28 | 4 |
| Otsuka America Pharmaceutical, Inc. | $160.43 | 2 |
| Ardelyx, Inc. | $120.21 | 1 |
| Acerta Pharma LLC | $44.42 | 2 |
| AKEBIA THERAPEUTICS INC | $24.61 | 1 |
| Fresenius USA Marketing, Inc. | $22.95 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (12)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $24.61 | 10/08/2024 | Education | Undisputed | 01/23/2026 | 1145833527 | CMS |
| Amgen Inc. | $9.07 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116044347 | CMS |
| Amgen Inc. | $9.02 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116044353 | CMS |
| Amgen Inc. | $4.10 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116044361 | CMS |
| Amgen Inc. | $141.09 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116044367 | CMS |
| Ardelyx, Inc. | $120.21 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146702944 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.93 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105482415 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.49 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104676705 | CMS |
| Fresenius USA Marketing, Inc. | $22.95 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154197892 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.26 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118966907 | CMS |
| Otsuka America Pharmaceutical, Inc. | $145.17 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118966909 | CMS |
| Travere Therapeutics, Inc. | $213.09 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149895853 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.